Status: Recruiting
Neoadjuvant Befotertinib Combined Bevacizumab or Platinum-based Double Chemotherapy for Resectable Locally-advanced EGFR Mutation-positive Non-Small Cell Lung Cancer
This study targeted patients with resectable stage II-IIIA non-small cell lung cancer with EGFR mutation
Participants needed: 60
Trial details
Phase: Phase 2Age: 18+Biological sex: AllType: InterventionalSponsor: Peng ZhangUpdated: Jan 6, 2025Locations: 1
Eligibility criteria
NSCLC patient with EGFR sensitive mutation as confirmed by needle biopsy; [+9]
The patient has undergone any systemic anti-cancer treatment for NSCLC, includin... [+9]